Phaseline

Targets › CXCL8

CXCL8 (Interleukin-8): drug programs, companies and trials

4 programs from 4 companies in 5 trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Chemotactic factor that mediates inflammatory response by attracting neutrophils, basophils, and T-cells to clear pathogens and protect the host from infection. Also plays an important role in neutrophil activation. (UniProt, P10145)

Open in Phaseline: the race on CXCL8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAdakitug (BMS-986253)
Interleukin-8 inhibitor
CXCL8Phase 2Pancreatic Cancer; Head and Neck Squamous Cell CarcinomaDec 2026
Icahn School of Medicine at Mount SinaiAdakitug (BMS-986253)
Interleukin-8 inhibitor
CXCL8Phase 2Non-small Cell Lung CancerJul 2028
The Netherlands Cancer InstituteAdakitug (BMS-986253)
Interleukin-8 inhibitor
CXCL8Phase 2Colon CarcinomaMar 2032
Yana NajjarAdakitug (BMS-986253)
Interleukin-8 inhibitor
CXCL8Phase 1MelanomaAug 2027

Conditions

Non-small Cell Lung Cancer (1) Pancreatic Cancer (1) Head and Neck Squamous Cell Carcinoma (1) Colon Carcinoma (1) Melanoma (1)

Modalities

mixed (4)

Companies

Icahn School of Medicine at Mount Sinai (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) The Netherlands Cancer Institute (1) Yana Najjar (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.